Patents by Inventor Christophe Moinet

Christophe Moinet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8431556
    Abstract: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Grant
    Filed: July 3, 2010
    Date of Patent: April 30, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christophe Moinet, Marc Courchesne, Liliane Halab, Nathalie Chauret, Laval Chan Chun Kong
  • Patent number: 8269026
    Abstract: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Grant
    Filed: July 3, 2010
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christophe Moinet, Liliane Halab, Nathalie Turcotte, Monica Bubenik, Marc Courchesne, Carl Poisson, Oswy Z. Pereira, Paul Nguyen-Ba, Bingcan Liu, Nathalie Chauret, Caroline Cadilhac, Laval Chan Chun Kong
  • Patent number: 8124613
    Abstract: Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R?1, and R?2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: February 28, 2012
    Assignee: Virochem Pharma Inc.
    Inventors: Christophe Moinet, Charles Blais, Monica Bubenik, Laval Chan Chun Kong, Marc Courchesne, Oswy Z. Pereira, Réal Denis, Louis Vaillancourt, Constantin G. Yannopoulos
  • Patent number: 8110574
    Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: February 7, 2012
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christophe Thurieau, Jérôme Gonzalez, Christophe Moinet
  • Patent number: 8076349
    Abstract: Compounds according to formula (I): wherein A, R1 and R2 are as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: December 13, 2011
    Assignee: Virochem Pharma Inc.
    Inventors: Laval Chan Chun Kong, Christophe Moinet, Marc Courchesne, Louis Vaillancourt, Monica Bubenik
  • Patent number: 7960403
    Abstract: Compounds according to formula (I): wherein A, R1, R2 and R3 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: June 14, 2011
    Assignee: Virochem Pharma Inc.
    Inventors: Laval Chan Chun Kong, Christophe Moinet, Marc Courchesne, Louis Vaillancourt, Charles Blais, Monica Bubenik
  • Publication number: 20110105546
    Abstract: Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R?1, and R?2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.
    Type: Application
    Filed: June 14, 2007
    Publication date: May 5, 2011
    Inventors: Christophe Moinet, Charles Blas, Monica Bubenik, Laval Chan Chun Kong, Marc Courchesne, Oswy Pereira, Réal Denis, Louis Vaillancourt, Constantin Yannopoulos
  • Publication number: 20110077251
    Abstract: The invention relates to 17? lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infection by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Application
    Filed: August 16, 2010
    Publication date: March 31, 2011
    Inventors: Christophe Moinet, Bingcan Liu, Liliane Halab, Nathalie Turcotte, Real Denis, Carl Poisson, Paul Nguyen-Ba, Monica Bubenik, Laval Chan Chun Kong
  • Publication number: 20110077228
    Abstract: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Application
    Filed: July 3, 2010
    Publication date: March 31, 2011
    Inventors: Christophe Moinet, Marc Courchesne, Lilliane Halab, Nathalie Chauret, Laval Chan Chun Kong
  • Publication number: 20110077227
    Abstract: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Application
    Filed: July 3, 2010
    Publication date: March 31, 2011
    Inventors: Christophe Moinet, Liliane Halab, Nathalie Turcotte, Monica Bubenik, Marc Courchesne, Carl Poisson, Oswy Z. Pereira, Paul Nguyen-Ba, Bingcan Liu, Nathalie Chauret, Caroline Cadilhac, Laval Chan Chun Kong
  • Publication number: 20110059971
    Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Type: Application
    Filed: November 15, 2010
    Publication date: March 10, 2011
    Applicant: IPSEN S.A.S.
    Inventors: Christophe THURIEAU, Jérôme Gonzalez, Christophe Moinet
  • Patent number: 7858789
    Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: December 28, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christophe Thurieau, Jérôme Gonzalez, Christophe Moinet
  • Publication number: 20100286183
    Abstract: Novel compounds represented by formula (I): wherein R1, R2, R3 and R4 are as defined herein, and pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Application
    Filed: April 8, 2010
    Publication date: November 11, 2010
    Inventors: Laval CHAN CHUN KONG, Christophe Moinet, Louis Vaillancourt, Monica Bubenik
  • Patent number: 7709642
    Abstract: Novel compounds represented by formula (I): wherein R1, R2, R3 and R4 are as defined herein, and pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: May 4, 2010
    Assignee: Virochem Pharma, Inc.
    Inventors: Laval Chan Chun Kong, Christophe Moinet, Louis Vaillancourt, Monica Bubenik
  • Publication number: 20090149652
    Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Type: Application
    Filed: May 2, 2008
    Publication date: June 11, 2009
    Inventors: Christophe Thurieau, Jerome Gonzalez, Christophe Moinet
  • Publication number: 20090047238
    Abstract: Compounds according to formula, (I): wherein A, R1 and R2 are as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Application
    Filed: December 9, 2005
    Publication date: February 19, 2009
    Inventors: Laval Chan Chun Kong, Christophe Moinet, Marc Courchesne, Louis Vaillancourt, Monica Bubenik
  • Publication number: 20080267906
    Abstract: Compounds according to formula (I): wherein A, R1, R2 and R3 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Application
    Filed: December 9, 2005
    Publication date: October 30, 2008
    Inventors: Laval Chan Chun Kong, Christophe Moinet, Marc Courchesne, Louis Vaillancourt, Charles Blais, Monica Bubenik
  • Patent number: 7393861
    Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Type: Grant
    Filed: May 4, 2005
    Date of Patent: July 1, 2008
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Christophe Thurieau, Jérôme Gonzalez, Christophe Moinet
  • Patent number: 7351713
    Abstract: Compounds of formula I wherein R1, R2, R3, R4 and R5 are as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: April 1, 2008
    Assignee: Viro Chem Pharma, Inc.
    Inventors: Laval Chan Chun Kong, Ming-Qiang Zhang, Christophe Moinet, Marc Courchesne, Thumkunta Jagadeeswar Reddy, Melanie Proulx
  • Publication number: 20070299073
    Abstract: The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.
    Type: Application
    Filed: May 22, 2007
    Publication date: December 27, 2007
    Inventors: Christophe Thurieau, Lydie Poitout, Marie-Odile Galcera, Thomas Gordon, Barry Morgan, Christophe Moinet